8 results about "Hearing disorder" patented technology

The present disclosure generally relates to compositions comprising dihexa and methods for making or using said compositions. In some aspects, the compositions disclosed herein may comprise one or more additional active ingredients, including lipoic acid, spadin peptide, and / or phenyl-N-tert-butylnitrone. Compositions such as these may be used in certain embodiments, for example, to enhances a subject's hearing or to treat a hearing disorder, etc. In some embodiments, the compositions are topical compositions configured to treat hearing loss via administration, e.g., to the skin behind the outer ear or directly to the eardrum of a subject, etc. In some cases, the compositions disclosed herein may comprise one or more excipients to aid in transdermal delivery. For instance, in certain embodiments, the compositions comprise lecithin and / or other components that may facilitate delivery through the skin. Other aspects are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

The invention of a device and system for reduction of tinnitus defects and hearing disorders in the ear and to correct the defects along with real-time feedback with the help of brain output signal recording technology to determine the amount of corrections is related to a device and system to control and reduce hyperacusis, tinnitus and hearing loss and a flexible wearable device that can be placed on a patient's head and also is a portable wearable device that can be connected to a mobile phone and a pair of true wireless earbuds wirelessly. This invention is a system of applying a magnetic field to the auditory cortex of the human brain to reduce hearing defects. This hat is able to simultaneously treat the patient with rTMS and monitor brain activity using fNIRS technology so that it provides accuracy in magnetic stimulation and monitoring of brain reactions.

This invention provides drugs and methods for preventing or reversing hearing loss. [Solution] A composition comprising at least two different nucleic acid vectors, each of which comprises a coding sequence encoding a different portion of the otoferrin protein, and the use of these compositions for treating hearing loss in a subject are provided herein. This disclosure is based on the discovery that a composition comprising at least two different nucleic acid vectors, each of which comprises a coding sequence encoding a different portion of the otoferrin protein, can be used to generate a sequence encoding an active otoferrin protein (e.g., full-length otoferrin protein) in mammalian cells, thereby enabling the treatment of asymptomatic sensorineural hearing loss in a subject in need.

The invention belongs to the technical field of gene engineering, biomedicine and molecular diagnosis, and discloses a hearing disorder related HSD17B7 gene mutant and application thereof, the HSD17B7 gene mutant is an autosomal dominant mutant, and the mutation site of the HSD17B7 gene mutant is that the 544th nucleotide G of an HSD17B7 gene coding region on a human 10th chromosome is mutated into T (c.544Ggt; and the 182th amino acid in the protein sequence is mutated from glutamic acid E to a termination codon (p.E182 *). Through exon group sequencing analysis and animal experiment verification on members of the deafness disease family, the invention determines that the mutation has obvious correlation with deafness for the first time, reveals the key effect of the mutation as deafness causing mutation, and constructs a diagnostic kit capable of early identifying the mutation according to the key effect. The method can be widely applied to screening and molecular diagnosis of deafness high-risk groups, and has important scientific research value and clinical application prospect.

The present disclosure provides polynucleotides containing a TMPRSS3 promoter of a region capable of specifically expressing a transgene in cochlear hair cells and sensory supporting cells. The disclosure also provides nucleic acid vectors containing these promoters operably linked to a polynucleotide encoding a polypeptide. The present disclosure provides compositions and methods for specifically inducing transgene expression in inner ear cells, such as hair cells and sensory supporting cells. The compositions described herein can be administered to a subject to treat a condition caused by inner ear cell dysfunction, such as hearing loss or vestibular dysfunction.

Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and Cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of Cisplatin- or noise-induced hearing loss. In one aspect, use of Niclosamide, Ingenol, and Elesclomol as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and / or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Provided herein are methods and compositions for the treatment of hearing disorders by administration of a combination of two or more calcium channel blockers.

The present invention provides a method for treating hearing loss in a subject suffering from an auditory condition and a method for enhancing the effectiveness of a cochlear implant in a subject having an auditory condition, comprising administering a population of auditory cells obtained by inducing the differentiation of pluripotent cells presumed to have an auditory fate into the inner ear of the subject.